Clinical trials · North Carolina
Solid Tumor Cancer clinical trials in North Carolina
We’re tracking 110 recruiting solid tumor cancer studies with a site in North Carolina — including Early Phase 1, Phase 1 and Phase 1/Phase 2 studies, each written for real people, not researchers.
Recruiting studies in North Carolina
- NCT05118789RecruitingPhase 1/Phase 2
Study drug for ROS1-positive lung or solid tumors
This Phase 1/2 study tests zidesamtinib (NVL-520), a medicine meant to attack cancers that have a ROS1 genetic change. It’s for people with advanced or metastatic ROS1-rearranged NSCLC (lung cancer) and, in one group, other solid tumors.
Charlotte, North CarolinaAges 12 years+ - NCT05245500RecruitingPhase 1
Study drug for solid tumors with MTAP gene deletion
This Phase 1 trial studies MRTX1719, a new medicine, in solid tumors that have a missing MTAP gene (MTAP deletion). It aims to find the safest dose and check how the drug affects the tumor.
Chapel Hill, North CarolinaAges 18 years+ - NCT05384626RecruitingPhase 1/Phase 2
Study of an ALK-targeted drug for ALK-positive lung cancer
This early-stage study tests neladalkib (NVL-655), a medicine designed to attack ALK-positive cancer. It may help people with advanced ALK-mutated or ALK-rearranged solid tumors, especially ALK-positive non-small cell lung cancer.
Durham, North CarolinaAges 12 years+ - NCT05735080RecruitingPhase 1/Phase 2
INX-315 for advanced cancers with a specific gene change
This trial studies an experimental medicine (INX-315) given in an “open-label” way to people with advanced cancer that has not responded to prior treatment. It mainly looks at safety and side effects first, and also checks how well it works in cancers with a specific gene amplification.
Durham, North CarolinaAges 18 years+ - NCT06040541RecruitingPhase 1
Study of RMC-9805 for KRAS G12D solid tumors
This trial tests an experimental pill (RMC-9805) for people with solid tumors that have a specific KRAS G12D mutation. It's for those who have already tried other treatments and need new options.
Durham, North CarolinaAges 18 years+ - NCT06108050RecruitingPhase 1
Testing a new drug alone and with pembrolizumab for advanced solid tumors
This trial tests a new drug called JZP898, given alone or with pembrolizumab, for adults with advanced solid tumors that have stopped responding to other treatments. It aims to see if this combination can help shrink tumors or slow their growth.
Durham, North CarolinaAges 18 years+ - NCT06253871RecruitingPhase 1
Study of IAM1363 for HER2 Cancers
This trial tests a new oral drug called IAM1363 for people with HER2-altered cancers that have stopped responding to previous treatments. The goal is to see if the drug is safe and how well it works against these cancers.
Durham, North CarolinaAges 18 years+ - NCT06515613RecruitingPhase 1
Testing CTIM-76 for recurrent ovarian and other advanced cancers
This trial tests a new drug, CTIM-76, in people whose ovarian, testicular, or endometrial cancer has come back and is not responding to standard treatments. It aims to see if the drug can shrink tumors or stop them from growing.
Durham, North CarolinaAges 18 years+ - NCT06545331RecruitingPhase 1
A study of XB010 for advanced solid tumors
This trial tests an investigational drug called XB010 for people with solid tumors that have spread or cannot be removed by surgery. It aims to see if XB010 is safe and effective for several cancer types, including lung, breast, head and neck, and esophageal cancers.
Huntersville, North CarolinaAges 18 years+ - NCT06778863RecruitingPhase 1
A study of CLSP-1025 for adults with certain solid tumors
This trial tests a new drug called CLSP-1025 for people with advanced solid tumors that have a specific change in the p53 gene (R175H). The drug targets this change to help fight the cancer.
Durham, North CarolinaAges 18 years+ - NCT06835569RecruitingPhase 1
ALTA3263 for advanced KRAS-mutated solid tumors
This trial tests an experimental pill called ALTA3263 for adults with advanced solid tumors that have a specific KRAS mutation. It's for people who have already tried other treatments or can't take them.
Durham, North CarolinaAges 18 years+ - NCT06840886RecruitingPhase 1
Testing a new drug for advanced solid tumors
This study tests an experimental drug called PHST001 for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it is safe and if it can help shrink tumors.
Durham, North CarolinaAges 18 years+ - NCT06896162Recruiting
Genetic test to guide first or second treatment for advanced cancer
This study looks at whether using a detailed genetic test of your tumor can help pick the best first or second treatment for advanced lung, colon, breast, or bladder cancer. The goal is to see if this personalized approach helps people live longer.
Chapel Hill, North CarolinaAges 18 years+ - NCT06898450RecruitingPhase 1/Phase 2
Study of new drug NDI-219216 for advanced solid tumors
This study tests a new drug called NDI-219216 for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it is safe and can help shrink or control the cancer.
Winston-Salem, North CarolinaAges 18–99 - NCT06993844RecruitingPhase 1/Phase 2
Study of ETX-636 for advanced solid tumors with PIK3CA mutation
This trial tests an experimental drug called ETX-636 in people whose cancer has a specific gene change (PIK3CA mutation) and has not responded to at least one prior treatment. The goal is to see if the drug can shrink tumors or stop them from growing.
Huntersville, North CarolinaAges 18 years+ - NCT07030257RecruitingPhase 1/Phase 2
Study of CP-383 for advanced solid tumors
This study tests a new drug called CP-383 for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it can shrink tumors or slow cancer growth, especially for certain cancers with genetic changes.
Huntersville, North CarolinaAges 18 years+ - NCT07317505RecruitingPhase 1
Study of JMT108 for Advanced Solid Tumors
This trial tests a new drug called JMT108 in people with advanced solid tumors that have not responded to standard treatments or for which no standard treatment exists. The study aims to see if the drug is safe and how it affects the body.
Huntersville, North CarolinaAges 18 years+ - NCT03093116RecruitingPhase 1/Phase 2
Repotrectinib for ALK, ROS1, or NTRK tumor gene changes
This trial studies repotrectinib, a targeted medicine, in people with advanced solid tumors that have specific gene rearrangements (ALK, ROS1, or NTRK). It may help shrink tumors or control cancer growth based on the patient’s tumor genetic result.
Goldsboro, North CarolinaAges 12 years+ - NCT05098132RecruitingPhase 1/Phase 2
STK-012 drug for advanced lung cancer and other tumors
This trial tests STK-012 (alone and with other treatments) in people with advanced cancers, especially non-small cell lung cancer. It may help by activating the immune system to recognize and fight the tumor.
Durham, North CarolinaAges 18 years+ - NCT07218003Enrolling by invitationPhase 1
Study of RNDO-564 alone or with pembrolizumab for bladder cancer
This trial tests an experimental drug, RNDO-564, either by itself or combined with another drug (pembrolizumab), for people with advanced bladder cancer or other solid tumors that have stopped responding to standard treatments. The goal is to see if it can shrink tumors or slow cancer growth.
Huntersville, North CarolinaAges 18 years+ - NCT06635785RecruitingPhase 1/Phase 2
AI-081 for advanced solid tumors
This trial tests a new drug called AI-081 that targets the immune system and tumor blood vessels. It is for people with advanced solid tumors who have not responded to other treatments or cannot take them.
Chapel Hill, North CarolinaAges 18 years+ - NCT07749586RecruitingPhase 1/Phase 2
Study of ARV-6723 alone or with pembrolizumab for advanced solid tumors
This trial tests an experimental drug called ARV-6723, alone or with another drug called pembrolizumab, for people with advanced solid tumors that have not responded to other treatments. The goal is to see if these combinations can help shrink tumors or slow their growth.
Huntersville, North CarolinaAges 18 years+ - NCT06400485RecruitingEarly Phase 1
Testing AMT-676 for advanced solid tumors
This trial tests a new drug called AMT-676 in people with advanced solid tumors that have not responded to standard treatments. It may be an option for those with certain cancers like colorectal, stomach, or pancreatic cancer.
Huntersville, North CarolinaAges 18 years+ - NCT05329103RecruitingPhase 1
Test drug PEEL-224 in advanced solid tumor cancers
This Phase 1 study tests PEEL-224 in people whose solid tumors are advanced and have not responded to standard treatments (or have no approved standard option). It focuses on safety and early signs of whether the drug can help shrink tumors.
Huntersville, North CarolinaAges 18 years+
Solid Tumor Cancer trials by city in North Carolina
Where these studies are running in North Carolina
Institutions with a site for the recruiting solid tumor cancer studies listed above.
- Carolina BioOncology Institute · 7 studies
- Duke Cancer Institute · 5 studies
- Duke Cancer Center · 3 studies
- Levine Cancer Institute · 3 studies
- Duke University Medical Center · 2 studies
- University of North Carolina at Chapel Hill · 2 studies
- Atrium Health Wake Forest Baptist Medical Center (Wake Forest Baptist)
- Carolina Biooncology Institute
What taking part in a solid tumor cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Solid Tumor Cancer trials in other states
Common questions
- Are there solid tumor cancer clinical trials in North Carolina?
- Yes. We're currently tracking 110 recruiting solid tumor cancer studies with a site in North Carolina, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a solid tumor cancer study in North Carolina?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in North Carolina to take part?
- Not necessarily. These studies have a site in North Carolina, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a solid tumor cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New solid tumor cancer studies open in North Carolina regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.